tipifarnib has been researched along with byl719 in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (byl719) | Trials (byl719) | Recent Studies (post-2010) (byl719) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 222 | 27 | 218 |
| Protein | Taxonomy | tipifarnib (IC50) | byl719 (IC50) |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | 0.5983 | |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | Homo sapiens (human) | 0.7672 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 2.2 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 0.0348 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | 1.663 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 2.2305 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | 0.1966 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Rattus norvegicus (Norway rat) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adkins, DR; Bruce, JY; Burrows, F; Chan, S; Dale, S; Dayoub, A; Gascó Hernández, A; Gutkind, JS; Hanna, GJ; Ho, AL; Kessler, L; Koshizuka, K; Malik, S; McCloskey, A; Patel, HV; Perez, CA; Reilly, Q; Saunders, A; Smith, AE; Soifer, HS; Villaflor, V; Wang, JZ; Wang, Z | 1 |
1 other study(ies) available for tipifarnib and byl719
| Article | Year |
|---|---|
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Topics: Biomarkers; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras); Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases | 2023 |